Genetic Risk Factors in AML Prognosis

The efficacy of induction therapy was assessed using response criteria proposed by European Leukemia Net [20 (link)]. Overall survival (OS) was defined as the time from diagnosis to death from any cause. Relapse-free survival (RFS) was defined as time calculated from the achievement of remission until the date of relapse or death from any cause. The probabilities of OS and RFS rates were estimated using the Kaplan–Meier method. Genetic risk groups were compared with respect to these parameters using the log-rank test. In the case of WT1 rs16754 variant, deviations in genotype frequencies in controls (healthy blood donors) and cases (AML patients) from Hardy–Weinberg equilibrium (HWE) were assessed by Chi-squared test with Yates’s correction for the groups with less than five patients [28 ]. For 95% confidence interval (CI), we assumed p = 0.05 and χ² = 3.84; therefore, if the χ² ≤ 3.84 and the corresponding p ≥ 0.05, then the population is in HWE, as described previously by Zmorzynski et al., 2019 [29 (link)]. Differences with a p value less than 0.05 were considered statistically significant. Statistica software version 12.0 (Statsoft, Tulsa, AK, USA) was used for statistical analysis.